As of November 6, 2026, Mobia Medical, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 15, 2026 to October 16, 2026, naming 3 appointments. The latest filing names Reza Zadno, appointed (Form 8-K, October 16, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Mobia Medical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Reza Zadno · 8-K/A, 2026-10-16
- · In / out: Reported · Person: not named in the filing · 8-K/A, 2026-10-16
- · In / out: In · Person: Myriam J. Curet · Role: Director · Effective: 2026-07-30 · 8-K, 2026-08-03
- · In / out: In · Person: Reza Zadno · Role: Director · 8-K, 2026-07-15
Mobia Medical, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-15 to 2026-10-16. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Mobia Medical, Inc. files it.
Also on the record for Mobia Medical, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by Clay M. Heighten, MD | 11.1% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G, by Casey M. Tansey | 11.6% of the class | 5%+ stakes | Source |
| May 18, 2026 | Stake report, Schedule 13G, by Synapse Investment, LP | 6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13D, by Osage University Partners III, LP | 10.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Gilde Healthcare Holding B.V. | 6.3% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13D, by Longitude Capital Partners V, LLC | 9.8% of the class | 5%+ stakes | Source |
| March 14, 2025 | Form D, private offering | $32.50M sold | Form D page | Source |
Selling to them or working with them? See who runs Mobia Medical, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Mobia Medical, Inc. and the records around it.
Mobia Medical, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Mar 2025
- Who owns it
Companies that share a holder
- Gilde Healthcare Holding B.V. also filed stake reports on 2 other companies: Shoulder Innovations, Inc. (Aug 2026), SpyGlass Pharma, Inc. (Feb 2026)
- U.S. Venture Partners XII, L.P. also filed stake reports on 2 other companies: Shoulder Innovations, Inc. (Nov 2025), Carlsmed, Inc. (Nov 2025)
- Longitude Capital Partners V, LLC also filed stake reports on 3 other companies: Entera Bio Ltd. (Aug 2026), CytomX Therapeutics, Inc. (May 2026), Veradermics, Incorporated (May 2026)
Watch Mobia Medical, Inc.
Get an email when Mobia Medical, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Mobia Medical, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Mobia Medical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mobia Medical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-16 | In | 8-K/A, 2026-10-16 | |||
| 2026-10-16 | Reported | not named in the filing | 8-K/A, 2026-10-16 | ||
| 2026-08-03 | In | Director | 2026-07-30 | 8-K, 2026-08-03 | |
| 2026-07-15 | In | Director | 8-K, 2026-07-15 |
Who leads Mobia Medical, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Myriam J. Curet, appointed, effective 2026-07-30 (filed 2026-08-03).
New leaders reset buying decisions — get the Full Report on Mobia Medical, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Mobia Medical, Inc., with the record behind each one.
Find candidates like Director at Mobia Medical, Inc.Every change, in the filing's words
Appointed: Reza Zadno
On October 15, 2026, Mobia's Board of Directors appointed Reza Zadno, Ph.D., to serve as a member of its audit committee, effective immediately.
- All other disclosures in that report remain unchanged.
- Dr. Zadno will continue serving on Mobia's compensation committee.
Reported
of Mobia Medical, Inc.'s ("Mobia") Current Report on Form 8-K filed on August 3, 2026, solely to report the committee appointment described below.
- All other disclosures in that report remain unchanged.
- On October 15, 2026, Mobia's Board of Directors appointed Myriam J. Curet, M.D., to serve as a member of its nominating and corporate governance committee, effective immediately.
Appointed: Myriam J. Curet, Director, effective 2026-07-30
Effective July 30, 2026, the Board of Directors (the " Board ") of Mobia Medical, Inc. (" Mobia ") increased the size of the Board from seven to eight members and appointed Myriam J. Curet, M.D. as a new member of the Board.
- Dr. Curet was appointed as a Class II director, with a term expiring at Mobia's 2028 annual meeting of stockholders or until her successor is duly elected and qualified, or until her earlier death, resignation, or removal.
- In connection with her appointment, the Board determined that Dr. Curet qualifies as an independent director under the applicable rules and regulations of the Securities and Exchange Commission and the listing standards of The Nasdaq Stock Market LLC.
- Dr. Curet has not been appointed to serve on any committee of the Board at this time.
- Dr. Curet served as Executive Vice President and Chief Medical Officer of Intuitive Surgical, Inc. (Nasdaq: ISRG), a global technology leader in minimally invasive care and robotic-assisted surgery, from November 2017 until her retirement in March 2026.
- She joined Intuitive Surgical in December 2005 as Chief Medical Advisor and served as its Senior Vice President and Chief Medical Officer from February 2014 to November 2017.
- Dr. Curet has served as a Clinical Professor of Surgery at Stanford University School of Medicine since 2015 and previously held a series of faculty positions in Stanford's Department of Surgery from 2000 to 2015, most recently as Professor of Surgery.
- She has also held a part-time clinical appointment at the Palo Alto Veterans Administration Medical Center since October 2010.
Appointed: Reza Zadno, Director
On July 14, 2026, the Board of Directors (the " Board ") of Mobia Medical, Inc. (" Mobia ") increased the size of the Board from six to seven members and appointed Reza Zadno, Ph.D. as a new member of the Board.
- Dr. Zadno was appointed as a Class III director, with a term expiring at Mobia's 2029 annual meeting of stockholders or until his successor is duly elected and qualified, or until his earlier death, resignation, or removal.
- The Board also appointed Dr. Zadno to serve as a member of the Compensation Committee of the Board.
- In connection with his appointment, the Board determined that Dr. Zadno qualifies as an independent director and satisfies the requirements to serve on the Compensation Committee, under the applicable rules and regulations of the Securities and Exchange Commission and the listing standards of The Nasdaq Stock Market LLC.
- In connection with his appointment, Dr. William Harrington resigned as a member of the Compensation Committee, such that the Compensation Committee now consists of Casey Tansey, Dana Mead and Dr. Zadno, with Mr. Tansey serving as chair.
- Dr. Zadno previously served as the President and Chief Executive Officer and a director of PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company, from February 2020 to September 2025.
- From September 2016 to November 2020, Dr. Zadno served as the President and Chief Executive Officer of Avedro, Inc., a public ophthalmology company now part of Glaukos Corporation (NYSE: GKOS), where he also served as a member of its board of directors from September 2016 to November 2020.
Tools for this story
Each opens in a new tab, filled in for Mobia Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.